Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103


Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Ruggiu M, Cassinat B, Kiladjian JJ, Raffoux E, Giraudier S, Robin M, Itzykson R, Clappier E, Michonneau D, de Fontbrune FS, de Latour RP, Ades L, Socié G.

Biol Blood Marrow Transplant. 2020 Feb 28. pii: S1083-8791(20)30105-1. doi: 10.1016/j.bbmt.2020.02.019. [Epub ahead of print]


Synergistic effects of PRIMA-1Met (APR-246) and Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, Giraudier S.

Haematologica. 2019 Sep 5. pii: haematol.2019.218453. doi: 10.3324/haematol.2019.218453. [Epub ahead of print]


Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.


Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.

Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques).

Br J Haematol. 2019 Nov;187(3):337-346. doi: 10.1111/bjh.16083. Epub 2019 Jul 4.


How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?

Cassinat B, Giraudier S, Kiladjian JJ.

Expert Rev Hematol. 2019 Jul;12(7):473-476. doi: 10.1080/17474086.2019.1623019. Epub 2019 Jun 4. No abstract available.


Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.

Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801482. doi: 10.1183/13993003.01482-2018. Print 2018 Dec. No abstract available.


Positive impact of molecular analysis on prognostic scores in essential thrombocythemia: a single center prospective cohort experience.

Luque Paz D, Mansier O, Riou J, Conejero C, Roy L, Belkhodja C, Ugo V, Giraudier S.

Haematologica. 2019 Apr;104(4):e134-e137. doi: 10.3324/haematol.2018.197699. Epub 2018 Oct 18. No abstract available.


Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ.

Blood Cancer J. 2018 Oct 4;8(10):94. doi: 10.1038/s41408-018-0133-0.


Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.

Maslah N, Verger E, Schlageter MH, Miclea JM, Kiladjian JJ, Giraudier S, Chomienne C, Cassinat B.

Ann Hematol. 2019 Jan;98(1):111-118. doi: 10.1007/s00277-018-3499-y. Epub 2018 Sep 26.


Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features.

Guadall A, Lesteven E, Letort G, Awan Toor S, Delord M, Pognant D, Brusson M, Verger E, Maslah N, Giraudier S, Larghero J, Vanneaux V, Chomienne C, El Nemer W, Cassinat B, Kiladjian JJ.

Thromb Haemost. 2018 Sep;118(9):1586-1599. doi: 10.1055/s-0038-1667015. Epub 2018 Aug 13.


Adolescence/adult onset MTHFR deficiency may manifest as isolated and treatable distinct neuro-psychiatric syndromes.

Gales A, Masingue M, Millecamps S, Giraudier S, Grosliere L, Adam C, Salim C, Navarro V, Nadjar Y.

Orphanet J Rare Dis. 2018 Feb 1;13(1):29. doi: 10.1186/s13023-018-0767-9. Review.


Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.

Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E.

Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. No abstract available.


Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.


Mechanisms of Thrombocytopenia During Septic Shock: A Multiplex Cluster Analysis of Endogenous Sepsis Mediators.

Bedet A, Razazi K, Boissier F, Surenaud M, Hue S, Giraudier S, Brun-Buisson C, Mekontso Dessap A.

Shock. 2018 Jun;49(6):641-648. doi: 10.1097/SHK.0000000000001015.


Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.


Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.

Partouche N, Conejero C, Barathon Q, Moroch J, Tulliez M, Cordonnier C, Giraudier S.

Hematol Oncol. 2018 Feb;36(1):336-339. doi: 10.1002/hon.2431. Epub 2017 May 29.


Pseudotyping Serotype 5 Adenovirus with the Fiber from Other Serotypes Uncovers a Key Role of the Fiber Protein in Adenovirus 5-Induced Thrombocytopenia.

Raddi N, Vigant F, Wagner-Ballon O, Giraudier S, Custers J, Hemmi S, Benihoud K.

Hum Gene Ther. 2016 Feb;27(2):193-201. doi: 10.1089/hum.2015.154.


Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.

Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Amé S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX.

Lancet Haematol. 2015 Jan;2(1):e37-46. doi: 10.1016/S2352-3026(14)00027-1. Epub 2015 Jan 7.


Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.

Fossard G, Blond E, Balsat M, Morisset S, Giraudier S, Escoffre-Barbe M, Labussière-Wallet H, Heiblig M, Bert A, Etienne M, Drai J, Sobh M, Redonnet-Vernhet I, Lega JC, Mahon FX, Etienne G, Nicolini FE.

Haematologica. 2016 Mar;101(3):e86-90. doi: 10.3324/haematol.2015.135103. Epub 2015 Dec 3. No abstract available.


Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Kiladjian JJ, Giraudier S, Cassinat B.

Leukemia. 2016 Apr;30(4):776-81. doi: 10.1038/leu.2015.326. Epub 2015 Nov 25. Review.


Unexplained thrombocytosis: association of Baltimore polymorphism with germline MPL nonsense mutation.

Verger E, Teillet F, Conejero C, Letort G, Chomienne C, Giraudier S, Cassinat B.

Br J Haematol. 2016 Oct;175(1):167-9. doi: 10.1111/bjh.13840. Epub 2015 Nov 16. No abstract available.


Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ.

Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.


Lack of Transcription Factor p53 Exacerbates Elastase-Induced Emphysema in Mice.

Chrusciel S, Zysman M, Caramelle P, Tiendrebeogo A, Baskara I, Le Gouvello S, Chabot F, Giraudier S, Boczkowski J, Boyer L.

Am J Respir Cell Mol Biol. 2016 Feb;54(2):188-99. doi: 10.1165/rcmb.2014-0375OC.


Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.

Porter JB, El-Alfy M, Viprakasit V, Giraudier S, Chan LL, Lai Y, El-Ali A, Han J, Cappellini MD.

Eur J Haematol. 2016 Jan;96(1):19-26. doi: 10.1111/ejh.12540. Epub 2015 Jun 23.


A late onset sickle cell disease reveals a mosaic segmental uniparental isodisomy of chromosome 11p15.

Vinatier I, Martin X, Costa JM, Bazin A, Giraudier S, Joly P.

Blood Cells Mol Dis. 2015 Jan;54(1):53-5. doi: 10.1016/j.bcmd.2014.07.021. Epub 2014 Aug 20. Review.


JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Besancenot R, Roos-Weil D, Tonetti C, Abdelouahab H, Lacout C, Pasquier F, Willekens C, Rameau P, Lecluse Y, Micol JB, Constantinescu SN, Vainchenker W, Solary E, Giraudier S.

Blood. 2014 Sep 25;124(13):2104-15. doi: 10.1182/blood-2014-03-559815. Epub 2014 Aug 20.


B12 deficiency increases with age in hospitalized patients: a study on 14,904 samples.

Mézière A, Audureau E, Vairelles S, Krypciak S, Dicko M, Monié M, Giraudier S.

J Gerontol A Biol Sci Med Sci. 2014 Dec;69(12):1576-85. doi: 10.1093/gerona/glu109. Epub 2014 Jul 25.


Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation.

Girardot M, Pecquet C, Chachoua I, Van Hees J, Guibert S, Ferrant A, Knoops L, Baxter EJ, Beer PA, Giraudier S, Moriggl R, Vainchenker W, Green AR, Constantinescu SN.

Oncogene. 2015 Mar 5;34(10):1323-32. doi: 10.1038/onc.2014.60. Epub 2014 Mar 31.


Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms.

Lesteven E, Picque M, Conejero Tonetti C, Giraudier S, Varin-Blank N, Velazquez L, Kiladjian JJ, Cassinat B, Baran-Marszak F.

Blood. 2014 Jan 30;123(5):794-6. doi: 10.1182/blood-2013-10-532622. No abstract available.


Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L.

Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. No abstract available.


Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.

Delgado L, Giraudier S, Ortonne N, Zehou O, Cordonnier C, Hulin A, Chosidow O, Tulliez M, Valeyrie-Allanore L.

J Am Acad Dermatol. 2013 Nov;69(5):839-840. doi: 10.1016/j.jaad.2013.07.025. No abstract available.


Clinical utility gene card for: hereditary thrombocythemia.

Hussein K, Percy M, McMullin MF, Schwarz J, Schnittger S, Porret N, Martinez-Aviles LM, Paricio BB, Giraudier S, Skoda R, Lippert E, Hermouet S, Cario H.

Eur J Hum Genet. 2014 Feb;22(2). doi: 10.1038/ejhg.2013.117. Epub 2013 Jun 5. No abstract available.


Gelatin-alginate gels and their enzymatic modifications: controlling the delivery of small molecules.

Klak MC, Lefebvre E, Rémy L, Agniel R, Picard J, Giraudier S, Larreta-Garde V.

Macromol Biosci. 2013 Jun;13(6):687-95. doi: 10.1002/mabi.201200386. Epub 2013 Feb 19.


[Myeloproliferative disorders "Philadelphia negative" and JAK2V617F mutation: study of 15 cases in Togo].

Padaro E, Agbetiafa K, Delagnon Kueviakoe IM, Layibo Y, Amegbor K, Vovor A, Giraudier S, Sanogo I, Segbena AY.

Ann Biol Clin (Paris). 2012 Oct 1;70(5):591-4. doi: 10.1684/abc.2012.0747. French.


Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.

Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, Mahon FX.

Blood. 2012 Aug 30;120(9):1959-60. doi: 10.1182/blood-2012-02-408229. No abstract available.


How can cobalamin injections be spaced in long-term therapy for inborn errors of vitamin B(12) absorption?

Boina Abdallah A, Ogier de Baulny H, Kozyraki R, Passemard S, Fenneteau O, Lebon S, Rigal O, Mesples B, Yacouben K, Giraudier S, Benoist JF, Schiff M.

Mol Genet Metab. 2012 Sep;107(1-2):66-71. doi: 10.1016/j.ymgme.2012.07.007. Epub 2012 Jul 20.


Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN.

Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29.


The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V.

Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7.


FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis.

Cancer Res. 2011 Apr 15;71(8):2901-15. doi: 10.1158/0008-5472.CAN-10-1731. Epub 2011 Apr 12. Erratum in: Cancer Res. 2011 Jun 1;71(11):4049-50.


Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.

Evrard S, Bluteau O, Tulliez M, Rameau P, Gonin P, Zetterberg E, Palmblad J, Bonnefoy A, Villeval JL, Vainchenker W, Giraudier S, Wagner-Ballon O.

Blood. 2011 Jan 6;117(1):246-9. doi: 10.1182/blood-2010-07-294447. Epub 2010 Oct 13.


Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.


A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation.

Besancenot R, Chaligné R, Tonetti C, Pasquier F, Marty C, Lécluse Y, Vainchenker W, Constantinescu SN, Giraudier S.

PLoS Biol. 2010 Sep 7;8(9). pii: e1000476. doi: 10.1371/journal.pbio.1000476.


Isolated remethylation disorders: do our treatments benefit patients?

Schiff M, Benoist JF, Tilea B, Royer N, Giraudier S, Ogier de Baulny H.

J Inherit Metab Dis. 2011 Feb;34(1):137-45. doi: 10.1007/s10545-010-9120-8. Epub 2010 May 21. Review. Erratum in: J Inherit Metab Dis. 2011 Dec;34(6):1229. Dosage error in article text.


miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.

Girardot M, Pecquet C, Boukour S, Knoops L, Ferrant A, Vainchenker W, Giraudier S, Constantinescu SN.

Blood. 2010 Jul 22;116(3):437-45. doi: 10.1182/blood-2008-06-165985. Epub 2010 May 5.


Should transcobalamin deficiency be treated aggressively?

Schiff M, Ogier de Baulny H, Bard G, Barlogis V, Hamel C, Moat SJ, Odent S, Shortland G, Touati G, Giraudier S.

J Inherit Metab Dis. 2010 Jun;33(3):223-9. doi: 10.1007/s10545-010-9074-x. Epub 2010 Mar 30.


Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative disorders.

PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893.


Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.

Pecquet C, Staerk J, Chaligné R, Goss V, Lee KA, Zhang X, Rush J, Van Hees J, Poirel HA, Scheiff JM, Vainchenker W, Giraudier S, Polakiewicz RD, Constantinescu SN.

Blood. 2010 Feb 4;115(5):1037-48. doi: 10.1182/blood-2008-10-183558. Epub 2009 Dec 8.


Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators.

Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.


Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid.

Jullienne B, Vigant F, Muth E, Chaligné R, Bouquet C, Giraudier S, Perricaudet M, Benihoud K.

Gene Ther. 2009 Dec;16(12):1405-15. doi: 10.1038/gt.2009.97.


SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis.

Chaligné R, Tonetti C, Besancenot R, Marty C, Kiladjian JJ, Socié G, Bordessoule D, Vainchenker W, Giraudier S; French Intergroup for MPD.

Leukemia. 2009 Jun;23(6):1186-90. doi: 10.1038/leu.2009.22. Epub 2009 Feb 19. No abstract available.


Supplemental Content

Loading ...
Support Center